ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX) and its recently formed subsidiary BioTime Acquisition Corporation (BAC) jointly announced today that they have entered into a ...
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that its ...
The appointment of David Schlachet and Deborah Andrews to the BioTime Board of Directors fills two vacancies created by the resignations of Henry L. Nordhoff and Andrew von Eschenbach last week. Mr.
Paper and Related Patent Filings Are a Strategic Step Forward in the Development of the Company's ReCyte(TM) iPS Technology ALAMEDA, Calif., Mar 16, 2010 (BUSINESS WIRE) -- BioTime, Inc., a ...
BioTime announces two significant milestones within the last 30 days. A discussion with BioTime's CEO, Dr. Michael West, and its Chief Commercial Officer, Dr. William Tew, provides additional detail ...
Welcome to the BioTime, Inc. Third Quarter 2018 Conference Call. At this time, all participants are in a listen-only mode. An audio webcast of this call is available on the Investors Section of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results